Abstract
It has been shown that allogeneic hematopoietic stem cell transplantation (HSCT) can be one of the therapeutic options for patients with metastatic solid tumors, such as renal cancer. However, the development of relatively severe GVHD seems to be necessary to achieve tumor regression in the current setting. Thus, it is crucial to identify minor histocompatibility antigens (mHags) only expressed in tumor cells but not GVHD target organs. In this study, we examined whether three mHags: ACC-1 and ACC-2 encoded by BCL2A1, and HA-1 encoded by HMHA1, could serve as such targets for melanoma. Real-time PCR and immunohistochemical analysis revealed that the expression of both BCL2A1and HMHA1 in melanoma cell lines and primary melanoma cells was comparable to that of hematopoietic cells. Indeed, melanoma cell lines were efficiently lysed by cytotoxic T lymphocytes specific for ACC-1, ACC-2, and HA-1. Our data suggest that targeting mHags encoded not only by HMHA1, whose aberrant expression in solid tumors has been reported, but also BCL2A1 may bring about beneficial selective graft-versus-tumor effects in a population of melanoma patients for whom these mHags are applicable.
References
Feb 1, 1996·The New England Journal of Medicine·E GoulmyJ J van Rood
Mar 7, 1998·Science·J M den HaanE Goulmy
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M B AtkinsS A Rosenberg
Sep 14, 2000·The New England Journal of Medicine·R ChildsA J Barrett
Mar 16, 2002·The Cancer Journal·Richard Childs, Ram Srinivasan
Mar 21, 2002·Proceedings of the National Academy of Sciences of the United States of America·Andrew I SuJohn B Hogenesch
Apr 3, 2002·Nature Medicine·Anne M DickinsonEls Goulmy
Apr 20, 2002·Transplantation·Nobuharu FujiiMine Harada
Jun 18, 2002·Oncology·Tatyana VlaykovaSeppo Pyrhönen
Aug 7, 2002·The Journal of Experimental Medicine·Christoph A KleinEls Goulmy
Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Toshiro KurokawaAndreas Mackensen
Sep 21, 2002·Science·Mark E DudleySteven A Rosenberg
Oct 31, 2002·Seminars in Oncology·Jean-Pascal MachielsMarie Marchand
Nov 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·C YeeP D Greenberg
May 29, 2003·The Journal of Experimental Medicine·Yoshiki AkatsukaToshitada Takahashi
Jun 14, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Mikinori MiyazakiToshitada Takahashi
Feb 12, 2004·British Journal of Haematology·Tetsuya NishidaToshitada Takahashi
May 4, 2004·Nature Reviews. Cancer·Marie Bleakley, Stanley R Riddell
Aug 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael R BishopRonald Gress
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark E DudleySteven A Rosenberg
Jun 15, 2005·Expert Opinion on Biological Therapy·Alain Ravaud, Marie-Sarah Dilhuydy
Aug 16, 2005·Blood·Freke M KloosterboerJ H Frederik Falkenburg
Feb 25, 2006·Blood·Elisabeth H SlagerJ H Frederik Falkenburg
Mar 23, 2006·Annual Review of Immunology·Thierry BoonPierre van der Bruggen
Jul 5, 2006·British Journal of Cancer·D J GottliebC Traversari
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David F McDermott
Apr 6, 2007·Blood·Takakazu KawaseToshitada Takahashi
May 25, 2007·Cancer Science·Yoshiki AkatsukaToshitada Takahashi
Jun 6, 2007·Cancer Immunology, Immunotherapy : CII·Amir KhammariBrigitte Dréno
Citations
Feb 9, 2011·Immunology and Cell Biology·Marie Bleakley, Stanley R Riddell
Jul 9, 2011·PloS One·Kelly BroenHarry Dolstra
Dec 25, 2010·Acta Microbiologica Et Immunologica Hungarica·Joseph G Sinkovics
Sep 21, 2012·Expert Review of Hematology·Marie BleakleyStanley R Riddell
Oct 21, 2017·Blood·Robson G DossaMarie Bleakley
Nov 1, 2014·Melanoma Management·Léon C van KempenAlan Spatz
Jun 26, 2020·Frontiers in Pediatrics·Corinne SummersMarie Bleakley
Mar 19, 2020·Frontiers in Immunology·Yoshiki Akatsuka